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Research
There is strong epidemiological evidence that 
short-term air pollution exposure (i.e., < 24 hr 
to 3 weeks) is related to mortality and other 
cardio  vascular events (Brook et al. 2010). 
Much of this evidence involves exposure to 
ambient particulate matter (PM) with aero-
dynamic diameter ≤ 2.5 μm (PM2.5), which 
comprises many components and varies 
regionally. Contributions of specific compo-
nents and sources to these effects are not well 
understood but are critical for informing the 
develop  ment of regulations.
Short-term exposure studies often use sta-
tionary monitors to estimate exposure in a 
nearby region. However, specific components 
of traffic-related air pollution (TRAP) vary 
substantially within cities, and traffic variables 
may contribute to this variation (Brauer et al. 
2003; Clougherty et al. 2008; Kinney et al. 
2000). This suggests that a geographically 
based approach could substantially improve 
assessment of black carbon (BC) exposure. 
Long-term exposure to TRAP (i.e., aver-
ages ≥ 1 year) has also been associated with 
cardio  vascular mortality, often based on 
studies using nitrogen dioxide as a surrogate 
for traffic pollutants and spatial modeling of 
exposures (Brunekreef et al. 2009; Gehring 
et al. 2006; Yorifuji et al. 2010). In a Boston, 
Massachusetts–area case-crossover analysis, 
we reported an association between mortality 
and BC exposure on the day before death, 
using spatio  temporally modeled BC exposure 
estimates as a marker of TRAP (Maynard 
et al. 2007).
Intercellular adhesion molecule-1 (ICAM-1) 
and vascular cell adhesion molecule-1   
(VCAM-1) are markers of inflammation and 
endothelial function that are expressed on cell 
surfaces and are also found in soluble form in 
the plasma (sICAM-1 and sVCAM-1). These 
markers are independently and jointly associ-
ated with increased risk of cardio  vascular dis-
ease (Albert and Ridker 1999; Pradhan et al. 
2002; Rana et al. 2011; Ridker et al. 2003). 
Recent studies have reported associations 
between inflammatory markers and short-term 
exposure to TRAP, but studies have varied 
in both PM exposure type and inflamma-
tory markers examined (Delfino et al. 2008; 
Madrigano et al. 2010; Zeka et al. 2006).
Obesity and diabetes are becoming increas-
ingly prevalent, and these conditions may 
increase susceptibility to the adverse health 
effects of air pollution (Forastiere et al. 2008; 
O’Neill et al. 2005; Zanobetti and Schwartz 
2002). Prospective and randomized clini-
cal trials, as well as laboratory studies, have 
demon  strated that statins, a widely prescribed 
class of drugs with anti-inflammatory and anti-
oxidant activity (Haendeler et al. 2004), can 
decrease C-reactive protein (CRP), ICAM-1, 
and VCAM-1 levels (Albert et al. 2001; 
Blanco-Colio et al. 2007; Liang et al. 2008; 
Montecucco et al. 2009). Thus, it is plausible 
that statin use could attenuate pro  inflammatory 
effects of air pollution, and reduced effects of 
air pollution on inflammation and heart-rate 
variability among statin users compared with 
non  users have been reported (Schwartz et al. 
2005; Zeka et al. 2006).
The primary objective of the present 
study was to estimate the cumulative effects 
of exposure to TRAP over several weeks 
on inflammation and endothelial function. 
Previous findings based on BC measured at 
a central-site monitor suggested associations 
between inflammatory markers and air pollu-
tion exposure averaged over the prior 4 weeks 
(Zeka et al. 2006). Because BC concentration 
varies spatially and averaging over a longer 
period of time decreases the temporal varia-
tion in the data, we wanted to examine effects 
of 4- to 12-week average exposures estimated 
using a land-use regression model. We chose 
sICAM-1 and sVCAM-1 as outcomes because 
they reflect changes in inflammation, are asso-
ciated with cardio  vascular disease risk, and 
are relatively stable within individuals over 
4-week periods (Eschen et al. 2008).
We hypothesized that increases in 
  medium-term BC concentrations estimated by 
land-use regressions would be associated with 
an increased inflammatory response in elderly 
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Ba c k g r o u n d: Exposure to traffic-related air pollution (TRAP) contributes to increased cardio-
vascular risk. Land-use regression models can improve exposure assessment for TRAP.
oBjectives: We examined the association between medium-term concentrations of black carbon 
(BC) estimated by land-use regression and levels of soluble intercellular adhesion molecule-1 
(sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1), both markers of inflamma-
tory and endothelial response. 
Me t h o d s : We studied 642 elderly men participating in the Veterans Administration (VA) Normative 
Aging Study with repeated measurements of sICAM-1 and sVCAM-1 during 1999–2008. Daily 
estimates of BC exposure at each geocoded participant address were derived using a validated spatio-
temporal model and averaged to form 4-, 8-, and 12-week exposures. We used linear mixed models 
to estimate associations, controlling for confounders. We examined effect modification by statin use, 
obesity, and diabetes.
re s u l t s: We found statistically significant positive associations between BC and sICAM-1 for aver-
ages of 4, 8, and 12 weeks. An interquartile-range increase in 8-week BC exposure (0.30 μg/m3) was 
associated with a 1.58% increase in sICAM-1 (95% confidence interval, 0.18–3.00%). Overall asso-
ciations between sVCAM-1 and BC exposures were suggestive but not statistically significant. We 
found a significant interaction with diabetes—where diabetics were more susceptible to the effect 
of BC—for both sICAM-1 and sVCAM-1. We also observed an inter  action with statin use, which 
was statistically significant for sVCAM-1 and suggestive for sICAM-1. We found no evidence of an 
interaction with obesity.
co n c l u s i o n: Our results suggest that medium-term exposure to TRAP may induce an increased 
inflammatory/endothelial response, especially among diabetics and those not using statins.
key w o r d s : adhesion molecules, air, cardio  vascular, environmental, outdoor air, roadway proximity. 
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men in the Greater Boston area. We also exam-
ined whether that effect was modified by statin 
use, obesity, and diabetes.
Materials and Methods
Study population. We studied participants in 
the Normative Aging Study (NAS), a longi-
tudinal study established by the VA in 1963 
(Bell et al. 1972). In brief, the NAS enrolled 
2,280 men from the Greater Boston area who 
were initially free of known chronic medical 
conditions. All participants provided written 
informed consent, and the study was approved 
by the institutional review boards of all par-
ticipating institutions. Participants visited the 
Boston VA Hospital study center every 3 years 
to under  go physical examinations. At each 
of these visits, blood samples and extensive 
physical examination, laboratory, anthropo-
metric, and questionnaire data were collected. 
Information about cigarette smoking, medical 
history, and medication use were obtained 
by self-administered questionnaire. Each sub-
ject was interviewed to confirm the identity 
and purpose of medications used, and all new   
disease diagnoses were noted.
Diabetes was defined as a physician diag-
nosis of diabetes, and obesity was defined as 
a body mass index (BMI) of at least 30 kg/
m2. Self-reported data on diabetes status and 
statin use were updated at each study visit. In 
addition, BMI and obesity were updated based 
on height and weight measurements at each 
visit. Thus, NAS data reflect changes in disease   
status and medication use over time.
Measurements of sICAM-1 and sVCAM-1 
began in 1999. For the present study, we 
included the 642 NAS participants with at least 
one measurement of sICAM-1 and sVCAM-1 
and whose home address was in the Greater 
Boston area (1,423 total person-visits). Subjects 
who moved out of the area were excluded.
Measurements of sICAM‑1 and sVCAM‑1. 
Blood samples routinely collected during 
medical exam visits from 1999 through 2008 
were analyzed for sICAM-1 and sVCAM-1 in 
N. Rafai’s laboratory at Children’s Hospital 
Boston (Boston, MA). Plasma sICAM-1 and 
sVCAM-1 concentrations were meas  ured in 
duplicate using the enzyme-linked immuno-
sorbent assay (ELISA) method (R&D Systems, 
Minneapolis, MN), with a sensitivity of 
0.35 ng/mL for sICAM-1 and 2.0 ng/mL for 
sVCAM-1 (Lim et al. 1999).
BC exposure prediction. The BC exposure 
model and the stationary air monitors used 
to develop the model have been described 
in detail previously (Gryparis et al. 2007). 
Briefly, 82 sites were used; most sites meas-
ured BC continuously using aethalometers, 
and other sites collected particles on a filter 
over 24 hr and meas  ured elemental carbon 
(EC) using reflectance analysis. The monitor-
ing data used to develop our model included 
6,031 observations from 2,079 unique 
  exposure days.
Using a spatio  temporal model that we 
developed and validated previously (Gryparis 
et al. 2007), we estimated the 24-hr average 
BC concentration at each geocoded participant 
address. Predicted daily concentrations showed 
a > 3-fold range of variation in exposure across 
measurement sites (adjusted R2 = 0.83). A vali-
dation sample at 30 additional monitoring sites 
showed an average correlation of 0.59 between 
predicted and observed daily BC levels. We 
averaged the 24-hr predictions to form esti-
mates for the 4, 8, and 12 weeks before each 
participant visit. We also averaged the 24-hr 
predictions to form estimates for the 4-week 
average during the 5–8 weeks before the 
study visit and the 4-week average during the 
9–12 weeks before the study visit, which are 
components of the 8- and 12-week averages, to 
use as a sensitivity analysis.
Covariates in the BC prediction model 
included measures of land use for each address 
(cumulative traffic density within 100 m, popu-
lation density, distance to nearest major road-
way, and percent urbanization), geographic 
information system (GIS) location (latitude, 
longitude), daily meteorological factors (appar-
ent temperature, wind speed, and height of the 
planetary boundary layer), and other charac-
teris  tics (day of week, day of season). The 
Boston central-site monitor was also included as 
a predictor to reflect average pollutant concen-
trations over the entire region on each day.
Separate models were fit for warm and 
cold seasons. Interaction terms between the 
temporal meteorological predictors and source-
based geographic variables allowed for space–
time inter  actions. Regression splines allowed 
main effect terms to non  linearly predict expo-
sure levels, and thin-plate splines modeled the 
residual spatial variability not explained by the 
spatial predictors. A latent variable framework 
was used to integrate BC and EC exposure 
data, where BC and EC measurements were 
treated as surrogates of some true, unobserv-
able traffic exposure variable; see Gryparis 
et al. (2007) for further details.
Estimation of health effects. We log-trans-
formed sICAM-1 and sVCAM-1 levels to 
increase normality and stabilize variance in 
the residuals. Model covariates were selected 
a priori, and all models included age, BMI, 
diabetes, smoking status, pack-years, and sea-
son. We used mixed models to account for 
correlation among measurements on the same 
subject across different medical visits. Mixed 
models have the form
 Y ij = β0 + βlagei + β2BMIi  
    + … + βpBCij + ui + εij,  [1]
where Yij is log(sICAM-1) or log(sVCAM-1) 
in subject i on day j, and ui represents a 
subject-specific intercept that reflects unex-
plained hetero  geneity in the outcome. BC 
averages and model covariates are modeled as 
fixed linear effects, and ui is modeled as a ran-
dom effect. We assume that the ui are gener-
ated from a normal distribution with common 
variance, yielding the simple compound sym-
metry variance structure. This model requires 
estimation of two variance components, which 
represent between- and within-subject varia-
tion. Models with unbalanced data (i.e., vary-
ing numbers of repeated measurements on 
each subject) typically yield accurate estimates 
of within-subject variation, provided a suf-
ficient number of repeated measurements con-
tribute to the estimate.
Models used to examine effect modi-
fication by obesity, diabetes, and statin use 
included inter  action terms that allowed asso-
ciations between BC and the outcomes to vary 
among subgroups. Diabetes, obesity, and sta-
tin use were treated as time-varying covariates, 
where the status was updated at each visit to 
reflect changes since the last visit. The percent-
ages of subjects whose status changed for these 
factors over the study period were 3% for dia-
betes, 9% for obesity, and 21% for statin use. 
We also performed a sensitivity analysis to 
investigate whether the interaction with statin 
use was heavily influenced by the people who 
began taking statins after the study period 
began. Specifically, we limited the interaction 
analysis to the participants who never used 
statins during the study period (n = 284) and 
those who used statins throughout the entire 
study period (n = 223).
Because the outcomes were log-transformed, 
effect estimates are reported as percent changes 
in sICAM-1 and sVCAM-1 concentrations 
associated with a 0.30-μg/m3 increase in BC, 
which corresponds to the interquartile range 
(IQR) for average BC exposures over all three 
time intervals (4, 8, and 12 weeks). A level 
of α = 0.05 was used to determine statistical 
significance.
Results
Descriptive data. Subjects were elderly, with 
a mean age of 72 years (range, 56–100 years) 
at the first study visit (Table 1). Most subjects 
were overweight (median BMI, 27.5 kg/m2;   
range, 18–52 kg/m2). Average 4-week BC 
exposure estimates ranged from 0 to 3.26   
μg/m3 (mean ± SD, 0.42 ± 0.30 μg/m3; 
median, 0.37 μg/m3; IQR, 0.30 μg/m3). For 
both 8- and 12-week exposures, exposure 
estimates were 0.42 ± 0.29 μg/m3 (median, 
0.38 μg/m3; IQR, 0.30 μg/m3). Figure 1 illus-
trates the spatial distribution of predicted BC 
in the study area during an arbitrary 4-week 
period (February 2001). The distributions of 
BC exposures looked similar among subjects 
classified according to obesity, diabetes, sta-
tin use, or smoking status, and we found no Traffic particles and endothelial function
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significant differences in the mean BC expo-
sure assessed at baseline.
Regression analysis. We found signifi-
cant positive associations between sICAM-1 
and BC averaged over the previous 4, 8, and 
12 weeks (Table 2). Associations between aver-
age BC for 4, 8, and 12 weeks and sVCAM-1 
were in the same direction, with slightly 
smaller effect size, but were not statistically sig-
nificant. As a sensitivity analysis, we also esti-
mated the effects of BC exposure in weeks 5–8 
and weeks 9–12 separately. For sICAM-1, 
the association with the longer BC lags were 
positive with effect size slightly smaller than 
the effect size for weeks 1–4 and not quite sta-
tistically significant. A 0.30-μg/m3 increase in 
BC exposure during weeks 5–8 was associated 
with a 1.22% increase in sICAM-1 [95% con-
fidence interval (CI), –0.10% to 3.00%], and 
during weeks 9–12, with a 1.09% increase in 
sICAM-1 (95% CI, –0.18% to 2.38%). For 
sVCAM-1, the estimated effects for the longer 
lags had the same effect size and direction as 
the effects for weeks 1–4 but were not statisti-
cally significant (data not shown). Overall, we 
saw the same pattern of effects in the lagged 
4-week intervals, with only slight weakening 
in effect when the lags were considered indi-
vidually rather than cumulatively.
Regression analysis and interactions. 
When we examined the effect of BC on 
sICAM-1 and sVCAM-1 by diabetes status, 
we saw effects only among diabetics, whereas 
non  diabetics showed no effect (Figure 2; 
inter  action p-values < 0.05 for all models 
except 12-week BC and sVCAM-1). When 
we examined the effects of BC by statin use, 
interaction models suggested that effects 
were present only in participants who did 
not use statins, with little evidence of associa-
tions among statin users (Figure 3; inter  action 
p-values < 0.05 for sVCAM-1 only). In con-
trast, we found no difference in the estimated 
effect of BC by obesity status on either out-
come (data not shown).
We restricted our sensitivity analysis of 
statin use interaction to participants who 
never used statins or always used statins 
during the study period. The results were 
comparable, with the effect sizes estimated 
to be slightly larger in all categories in the 
restricted model, and statistically significant 
(data not shown). These differences could 
reflect some overall difference in health 
between statin users and non  users because 
statin use was not randomized.
Discussion
We found that address-specific BC expo-
sures averaged over 4, 8, and 12 weeks were 
positively associated with markers of inflam-
mation and endothelial dysfunction in this 
elderly cohort. Exposure estimates based 
on our validated land-use regression model 
are more accurate than estimates based on 
ambient monitoring, which are often used 
for cohorts of this size. Our analyses suggest 
that diabetics are more susceptible to adverse 
effects of TRAP than are non  diabetics, but 
we found no evidence of effect modification 
by obesity. In addition, we observed a null 
effect among participants who used statins 
Table 1. Characteristics of the NAS population at 
first visit.
Covariate Mean ± SD or n (%)
Age (years) 72.4 ± 7.0
BMI (kg/m2) 28.3 ± 4.2
Diabetes 126 (19.6)
Obesity 180 (28.0)
Statin use 242 (37.7)
Smoking status
Former smoker 657 (69.7)
Current smoker 28 (2.9)
Never smoker 258 (27.4)
Pack-yearsa 30.4 (27.9)
sICAM-1 (ng/mL) 295.4 ± 80.6
sVCAM-1 (ng/mL) 1058.9 ± 351.8
aFor current and former smokers.
Table 2. Estimated percent increase in sICAM-1 and sVCAM-1 levels per 0.3-μg/m3 increase in BC, for 4-, 
8-, and 12-week averages. 
sICAM-1 sVCAM-1
Time period Percent increase 95% CI Percent increase 95% CI
4 weeks 1.50 0.22 to 2.80* 1.00 –0.65 to 2.67
8 weeks 1.58 0.18 to 3.00* 1.20 –0.58 to 3.02
12 weeks 1.49 0.04 to 2.95* 1.26 –0.58 to 3.14
*p < 0.05.
Figure 1. Predicted average BC concentration in the Greater Boston area over a 4-week period.
Predicted BC (µg/m3)
0.03–0.18
0.18–0.24
0.24–0.29
0.29–0.35
0.35–0.42
0.42–0.48
0.48–0.56
0.56–0.64
0.64–0.87
0.87–2.5Alexeeff et al.
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and a positive association for those not taking 
statins, but further investigation is needed to 
clarify this potential effect.
TRAP and inflammatory response. Several 
studies have examined the effects of short-
term (i.e., < 24 hr to 3 weeks) TRAP and 
various markers of inflammation. For exam-
ple, in a large epidemiological study, daily 
increases in ambient PM levels were posi-
tively associated with plasma fibrinogen levels,   
with the strongest association observed in par-
ticipants with chronic obstructive lung dis-
ease (Schwartz 2001). In a study of a small 
(n = 29) elderly population, Delfino et al. 
(2008) examined inflammatory markers and 
PM components measured at each subject’s 
home for 1–9 days on average. The authors 
reported that several traffic-related compo-
nents were significantly associated with CRP 
and interleukin-6, and observed positive but 
non  significant associations with sICAM-1 
and sVCAM-1.
In other studies of NAS participants, traf-
fic-related PM (BC and organic carbon) expo-
sure has also been positively associated with 
plasma total homo  cysteine concentrations 
(Park et al. 2008), and this association is mod-
ified by poly  morphisms in genes related to 
oxidative stress (Ren et al. 2010). PM2.5 and 
BC averages of 1–3 days measured at the cen-
tral site have been associated with increased 
vascular cell adhesion in NAS participants 
(Madrigano et al. 2010). Traffic-related PM 
(particle number and BC) has also been posi-
tively associated with inflammatory markers 
(CRP, white blood cell count, sediment rate, 
and fibrinogen) in NAS participants, with 
stronger associations with particle numbers 
than with BC and stronger associations with 
BC averaged over 4 weeks than averaged over 
48 hr or 1 week (Zeka et al. 2006).
Few controlled studies of PM on human 
inflammatory response have been conducted, 
but one reported that plasma fibrinogen 
increased after exposure to urban PM (Ghio 
et al. 2000), and another reported that periph-
eral neutrophils, sVCAM-1, and sICAM-1 
increased after a 1-hr exposure to diesel PM 
(Salvi et al. 1999).
Mechanisms and interactions. Diabetics 
have impaired endothelial function com-
pared with non  diabetics (Calles-Escandon 
and Cipolla 2001), and there is increasing 
evidence that diabetics are more susceptible to 
the effects of air pollution. Inverse associations 
between 60-day average BC exposure and bra-
chial artery flow-mediated dilation (FMD) 
were stronger in diabetics than in non-
diabetics (O’Neill et al. 2005). Associations 
between 24-hr exposure to PM2.5 and FMD 
were stronger among diabetics with markers 
of severe insulin resistance compared with 
other diabetics (Schneider et al. 2008).
In contrast with our findings, obese 
NAS participants have been reported to have 
stronger associations between short-term BC 
exposure and plasma CRP, erythrocyte sedi-
ment rate (Zeka et al. 2006), and sVCAM-1 
(Madrigano et al. 2010) than non  obese   
participants.
Our finding that statin users are less sus-
ceptible than those not taking statins is gener-
ally consistent with other studies. In diabetics, 
stronger associations of PM2.5 and BC with 
sVCAM-1 were reported among those not 
using statins than in statin users (O’Neill et al. 
2007). Associations between CRP and traffic 
PM exposures of 5 and 9 days were reported 
to be stronger among those using statins than 
those not using statins (Delfino et al. 2008). 
Statins promote endothelial nitric oxide 
release, which reduces cell adhesion, thus 
suggesting a mecha  nism for this association. 
However, we cannot rule out the possibility 
that statin use is an indicator of health status 
or some other unmeasured factor that may 
explain why BC did not appear to influence 
sICAM-1 and sVCAM-1 in statin users.
The question of which CAM is most 
closely associated with PM remains unre-
solved. Differences in the associations 
reported in epidemiological studies of the two 
CAMs could reflect differences in cell types 
that express the molecules or differences in 
the process of cleavage and shedding from 
endothelial cells. In the present study, the 
effects on both sICAM-1 and sVCAM-1 
were consistent: The effect sizes were similar 
and the direction of the effects and the inter-
actions were the same, even though we found 
differences in statistical significance. Thus, our 
study does not support the idea of a differ-
ent under  lying mechanism for the effects of 
TRAP on these two CAMs.
The expression of both ICAM-1 and 
VCAM-1 on the surface of vascular endothe-
lial cells is associated with the formation of 
early athero  sclerotic lesions. Although the 
relationship between the degree of cellu  lar 
ICAM-1 and VCAM-1 expression and plasma 
concentrations of soluble forms is not entirely 
clear, multiple studies have shown that 
sICAM-1 and sVCAM-1 predict risk of car-
diovascular disease (Albert and Ridker 1999; 
Pradhan et al. 2002; Rana et al. 2011; Ridker 
et al. 2003). In a recent study investigating 
the variability of sICAM-1 and sVCAM-1 
measures over a 4-week period, Eschen et al. 
(2008) reported an estimated intra  subject 
variability of 7.6% for sICAM-1 and 9.5% for 
sVCAM-1, which suggests that these markers 
are relatively stable over a 4-week period.
Exposure estimation. A major advantage 
of the present study is the use of a validated 
land-use regression model to character-
ize the individual-level differences in expo-
sures instead of classifying exposure based on 
measure  ments at the nearest monitor, land-
use regression models without BC measure-
ments, or a weighted form of distance to 
roadway. Although the study is still limited by 
the lack of individual-level monitoring data at 
the home, our validation study suggests that 
our estimates are highly correlated with actual 
exposure measure  ments at locations in Boston 
other than those used to fit the model and 
are much more closely correlated with these 
measurements than are exposure estimates 
Figure 2. Estimated percent increase in sICAM-1 (A) and sVCAM-1 (B) levels by diabetic status, per 0.3-μg/m3 
increase in BC, for 4-, 8-, and 12-  week averages. 
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Figure 3. Estimated percent increase in sICAM-1 (A) and sVCAM-1 (B) levels by statin use, per 0.3-μg/m3 
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based on a central-site monitor. Although 
some exposure misclassification will still occur 
based on our model estimates, we expect that 
most of the residual error is Berkson type, 
based on a previous validation study for this 
model analyzing measure  ment error (Gryparis 
et al. 2009). Thus, we expect that the exposure 
misclassification will not bias effect estimates.
The lack of individual activity data also 
presents a limitation, but the NAS population 
consists of elderly men who spend a consider-
able amount of time at or near their home 
address compared with other population 
groups.
Our sensitivity analysis of the block lags 
of weeks 5–8 and weeks 9–12 shows slight 
attenuation compared with the cumulative 
lags, suggesting that the cumulative effect may 
be dominated by the more recent weeks. The 
effect sizes for cumulative exposures do not 
attenuate when averaged up to 12 weeks. The 
4-week block lags do not isolate the effects of 
those time windows because each week is cor-
related in both space and time; thus, future 
studies to model the specific contributions 
of different lag weeks would be bene  ficial in 
understanding these effects.
Sources and components. Many studies 
have examined PM at different diameters, but 
fewer studies have looked at which compo-
nents of PM are associated with adverse health 
effects. Our study links a health biomarker 
with BC, a specific component of PM2.5. In 
addition, we consider BC to be a surrogate 
for primary traffic PM (a specific source of air 
pollution), where the spatial variability of BC 
on a given day reflects the variability of traffic 
in the region, which is the basis of the BC 
model we developed and used for this study.
We did not examine other pollutants such 
as total PM2.5 or PM2.5 components other 
than BC in this study. We think it is unlikely 
that total PM2.5 or any other copollutant is 
driving the effect we observed for BC because 
the BC model is based largely on the daily 
spatial variation exhibited by BC. Other com-
ponents of PM2.5, such as sulfates and organic 
PM, are more homo  geneous over the study 
region. Although we cannot completely rule 
out confounding by copollu  tants or other 
factors, the correlation between the model-
predicted 4-week BC and the correspond-
ing 4-week averages of PM2.5 measured at 
the central site was low (0.108), which sup-
ports our belief that the effects observed are 
not driven by any temporal correlation with 
PM2.5 or one of its components.
Generalizability. A limitation of this study 
is the restricted demographics of the study 
population. Study subjects were all elderly 
men, most of them white. Thus, we cannot 
generalize our results to other populations. 
However, the elderly represent a particularly 
susceptible population, and the growth in the 
number and proportion of older adults in the 
United States is unprecedented: by 2030, the 
proportion of the U.S. population ≥ 65 years 
of age will double to about 71 million older 
adults, or one in every five Americans (U.S. 
Census 2005).
Conclusions
We observed positive associations between 
BC exposures and blood levels of sICAM-1 
and sVCAM-1, with statistically significant 
effect estimates for sICAM-1 in the popula-
tion as a whole and for sVCAM-1 among 
diabetics and participants who were not using   
statins. Effects of BC on both markers 
appeared to be limited to diabetics and pos-
sibly those not using statins. Overall, our 
results suggest that exposure to traffic PM 
over 4–12 weeks may induce an increased 
inflammatory and endothelial response, par-
ticularly among diabetics, and that statin use 
may be protective against this effect.
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